Mike Zumdahl is Senior Vice President, Market Access and Commercial Strategy of Fractyl Health, where he leads the development of reimbursement and health economic infrastructure for Revita®.
Most recently, Mr. Zumdahl was President of Commercial Access Partners, advising medtech companies on go-to-market strategy, health economics, and reimbursement. Prior to that, he led Global Health Economics, Market Access, and Government Affairs at Inari Medical before its acquisition by Stryker for approximately $4.9 billion in February 2025, helping create one of medtech's most successful market access build-outs for a novel procedural category.
Earlier in his career, he started as a sales representative at GSK, and then spent nearly a decade at Novo Nordisk in roles of increasing responsibility, including National Accounts and Government Payers, where he contributed to the company's Health Economics and Outcomes Research strategy and value-based contracting for GLP-1 therapies.
